Sanofi and Glaxo scrape a Covid vaccine latecomer
After a long wait the groups’ jab delivers mediocre efficacy.
Pfizer waits for paediatric Comirnaty data to mature
A look at the past week’s Covid winners and losers finds Pfizer, unusually, among the latter.
Another step backwards for Valneva
The group’s Covid vaccine, as well as Sanofi and Glaxosmithkline’s jab, might not reach Europe for some time.
Mitsubishi's Medicago heads for the Covid-19 booster queue
The Canadian subsidiary claims success in its pivotal trial, though capacity restraints will limit the jab’s role for now.
Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
No let-up in Covid-19 vaccine trials
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
